By: Xiaojuan Sha, Lijuan Sun, Jun Wu
Keywords: Avibactam; Ceftazidime; Intestinal barrier dysfunction; Inflammatory cytokines; Sepsis
DOI : 10.36721/PJPS.2026.39.6.153.1
Abstract: Background: Studies have confirmed that the progression of sepsis is closely related to intestinal barrier dysfunction, including intestinal mucosa ischemia and hypoxia, flora imbalance and epithelial cell apoptosis. Therefore, protecting the intestinal barrier function has become a key link in the comprehensive treatment of sepsis. Objectives: This study evaluated the impact of a novel ?-lactamase inhibitor compound preparation (ceftazidime/avibactam) on intestinal barrier function in sepsis patients. Methods: The study included 108 sepsis patients (January 2022?August 2025) and grouped them as an observation group (54 cases, ceftazidime/avibactam+dynamic nutritional support) and a control group (54 cases, Ceftazidime/Sulbactam+dynamic nutritional support). Of the outcome measures assessed, the 28-day all-cause mortality was primary, while ICU length of stay, mechanical ventilation time, antibiotic course, intestinal barrier function markers (DAO, LBP, Claudin-1) and inflammatory cytokines (IL-6, TNF-?) were secondary. Results: The results indicated lower 28-day all-cause mortality in the observation group vs the control group, along with shorter ICU length of stay, mechanical ventilation time and time to negative blood culture conversion (P<0.05). Concerning post-treatment intestinal barrier function, DAO, LBP and FC were lower while claudin-1 was higher in the observation group compared to the control group (P<0.05). Analysis of inflammatory factors also showed greater reductions in IL-1?, IL-6 and TNF-? in the observation group post-treatment (P<0.05). Conclusion: Ceftazidime/Avibactam plus dynamic nutritional support is instrumental in improving the intestinal barrier function of sepsis patients and alleviating inflammatory reactions, thus enhancing life safety.
[View Complete Article]
